Cellectis is designing next generation immunotherapies based on gene-edited CAR T-cells. Allogeneic product candidates are a future-defining shift in simplicity, availability, and cost effectiveness.
UCARTs are “off-the-shelf” allogeneic product candidates, whose production can be industrialized and thereby standardized with consistent pharmaceutical release criteria, over time and from batch to batch.
Our product candidates, based on gene-edited T-cells that express Chimeric Antigen Receptors, or CARs, seek to harness the power of the immune system to target and eradicate cancer cells.
Our manufacturing process obtains therapeutic UCART product candidates from healthy, tested and qualified donor T-cells, rather than from patient samples.